AbCellera Biologics (ABCL) Non-Current Assets: 2020-2025
Historic Non-Current Assets for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $660.9 million.
- AbCellera Biologics' Non-Current Assets rose 1.68% to $660.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $660.9 million, marking a year-over-year increase of 1.68%. This contributed to the annual value of $609.2 million for FY2024, which is 1.12% down from last year.
- According to the latest figures from Q3 2025, AbCellera Biologics' Non-Current Assets is $660.9 million, which was up 0.14% from $659.9 million recorded in Q2 2025.
- AbCellera Biologics' Non-Current Assets' 5-year high stood at $660.9 million during Q3 2025, with a 5-year trough of $220.5 million in Q1 2021.
- Its 3-year average for Non-Current Assets is $620.2 million, with a median of $616.1 million in 2023.
- In the last 5 years, AbCellera Biologics' Non-Current Assets surged by 102.26% in 2021 and then dropped by 10.77% in 2025.
- Over the past 5 years, AbCellera Biologics' Non-Current Assets (Quarterly) stood at $388.8 million in 2021, then surged by 32.58% to $515.4 million in 2022, then rose by 19.54% to $616.1 million in 2023, then dropped by 1.12% to $609.2 million in 2024, then increased by 1.68% to $660.9 million in 2025.
- Its Non-Current Assets was $660.9 million in Q3 2025, compared to $659.9 million in Q2 2025 and $579.2 million in Q1 2025.